GlassScriptPhysician profile
Reay H Brown
NPI 1275693459
$28,970.19
in general payments reported to CMS, 2019-2025
23 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 80% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,496 · 2020: $473 · 2021: $12K · 2022: $2,427 · 2023: $745 · 2024: $1,391 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,123.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $24,280.44 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $1,252.46 | 2019-2025 | Clareon, Rocklatan, Lensx |
| Abbvie INC. | $625.99 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Glaukos Corporation | $347.42 | 2019-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $308.93 | 2019-2025 | Cequa |
| Allergan, INC. | $297.11 | 2019-2022 | |
| New World Medical,INC. | $209.86 | 2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Dompe US, INC. | $189.41 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $184.96 | 2024-2025 | Vevye |
| Shire North American Group INC | $165.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $161.30 | 2019-2023 | |
| Biotissue Holdings INC. | $143.64 | 2023 | |
| Bausch & Lomb Americas INC. | $133.84 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Rxsight INC | $124.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.09 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $81.08 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.90 | 2019-2020 | |
| Thea Pharma INC. | $62.73 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $59.91 | 2022-2024 | Tecnis Iol |
| Oyster Point Pharma, INC. | $58.03 | 2023-2024 | Tyrvaya |
| Amgen INC. | $52.54 | 2024 | Tepezza |
| Kala Pharmaceuticals, INC. | $22.46 | 2021 | |
| Omeros Corporation | $19.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reay Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.